Determination of epirubicin and its metabolite epirubicinol in saliva and plasma by HPLC

Therapeutic Drug Monitoring

Volumn 25, Issue 4, 2003, Pages 433-440

  Dodde, Wilma I W ^a   Maring, Jan Gerard ^b,c   Hendriks, Gert ^a   Wachters, Floris M ^a   Groen, Harry J M ^a   De Vries, Elisabeth G E ^a   Uges, Donald R A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Bethesda Hospital   (Netherlands)

^c Diaconessen Hospital   (Netherlands)

Author keywords

Epirubicin; Epirubicinol; HPLC; Plasma; Saliva

Indexed keywords

2 PROPANOL; ANTHRACYCLINE DERIVATIVE; CHLOROFORM; DOXORUBICIN; DRUG METABOLITE; EPIRUBICIN; EPIRUBICINOL;

ACCURACY; ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; DILUTION; DRUG BLOOD LEVEL; DRUG SALIVA LEVEL; DRUG STABILITY; ELUTION; FREEZING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PRIORITY JOURNAL; SPECTROFLUOROMETRY; THAWING; VALIDATION PROCESS;

ANTIBIOTICS, ANTINEOPLASTIC; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOXORUBICIN; EPIRUBICIN; HUMANS; LINEAR MODELS; SALIVA; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, FLUORESCENCE;

EID: 0041766240     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200308000-00003     Document Type: Article

References (29)

1. Hortobágyi GN. Anthracyclines in the treatment of cancer: an overview. Drugs. 1997;54(suppl 4):1-7.
2. Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol. 1992;19:670-686.
3. Plosker GL, Faulds D. Epirubicin A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs. 1993;45:788-856.
4. Lilenbaum RC, Green MR. Novel chemotherapeutic agents in the treatment of non-small cell lung cancer. J Clin Oncol. 1993;11:1391-1402.
5. Celio LA, DiGregorio GJ, Ruch E, et al. Doxorubicin and 5-fluorouracil plasma concentrations and detectability in parotid saliva. Eur J Clin Pharmacol. 1983;24:261-266.
6. Allen A. The cardiotoxicity of chemotherapeutic drugs. Semin Oncol. 1992;19:529-542.
7. Holding JD, Lindup WE, Roberts NB, et al. Measurement of platinum in saliva of patients treated with cisplatin. Ann Clin Biochem. 1999;36:655-659.
8. Van Warmerdam LJ, van Tellingen O, ten Bokkel Huinink WW, et al. Monitoring carboplatin concentrations in saliva: a replacement for plasma ultrafiltrate measurements? Ther Drug Monit. 1995;17:465-470.
9. Slevin ML, Johnston A, Woollard RC, et al. Relationship between protein binding and extravascular drug concentrations of a water-soluble drug, cytosine arabinoside. J R Soc Med. 1983;76:365-368.
10. Bresolle F, Jacquet JM, Galtier M, et al. Doxorubicin and doxorubicinol plasma concentrations and excretion in parotid saliva. Cancer Chemother Pharmacol. 1992;30:215-218.
11. Milano G, Thyss A, Santini J, et al. Salivary passage of 5-fluorouracil during continuous infusion. Cancer Chemother Pharmacol. 1989;24:197-199.
12. Joulia JM, Pinguet F, Ychou M, et al. Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid. Eur J Cancer. 1999;35:296-301.
13. Holthuis JJ, Postmus PE, Van Oort WJ, et al. Pharmacokinetics of high dose etoposide (VP 16-213). Eur J Cancer Clin Oncol. 1986;22:1149-1155.
14. Gouyette A, Deniel A, Pico JL, et al. Clinical pharmacology of high-dose etoposide associated with cisplatin. Pharmacokinetic and metabolic studies. Eur J Cancer Clin Oncol. 1987;23:1627-1632.
15. Takahashi T, Fujiwara Y, Sumiyoshi H, et al. Salivary drug monitoring of irinotecan and its active metabolite in cancer patients. Cancer Chemother Pharmacol. 1997;40:449-452.
16. Slavik M, Wu J, Riley C. Salivary excretion of anticancer drugs. Ann NY Acad Sci. 1993;694:319-321.
17. Schroder H, Jensen KB, Brandsborg M. Lack of correlation between methotrexate concentrations in serum, saliva and sweat after 24 h methotrexate infusions. Br J Clin Pharmacol. 1987;24:537-541.
18. Steele WH, Stuart JF, Whiting B, et al. Serum, tear and salivary concentrations of methotrexate in man. Br J Clin Pharmacol. 1979;7:207-211.
19. Patterson AJ, Ritschel WA, Zellner D, et al. Methotrexate serum and saliva concentrations in patients. Int J Clin Pharmacol Ther Toxicol. 1981;19:381-385.
20. Ishii E, Yamada S, Higuchi S, et al. Oral mucositis and salivary methotrexate concentration in intermediate-dose methotrexate therapy for children with acute lymphoblastic leukemia. Med Pediatr Oncol. 1989;17:429-432.
21. Oliff A, Bleyer WA, Poplack DG. Methotrexate-induced oral mucositis and salivary methotrexate concentrations. Cancer Chemother Pharmacol. 1979;2:225-226.
22. Albertioni F, Rask C, Schroeder H, et al. Monitoring of methotrexate and 7-hydroxymethotrexate in saliva from children with acute lymphoblastic leukemia receiving high-dose consolidation treatment: relation to oral mucositis. Anticancer Drugs. 1997;8:119-124.
23. Rask C, Albertioni F, Schroder H, et al. Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: relation to pharmacokinetic parameters of methotrexate. Pediatr Hematol Oncol. 1996;13:359-367.
24. Svojanovsky SR, Egodage KL, Wu J, et al. High sensitivity ELISA determination of taxol in various human biological fluids. J Pharm Biomed Anal. 1999;20:549-555.
25. Holthuis JJ, de Vries LG, Postmus PE, et al. Pharmacokinetics of high-dose teniposide. Cancer Treat Rep. 1987;71:599-603.
26. Jusko W, Milsap R. Pharmacokinetic principles of drug distribution in saliva. Ann N Y Acad Sci. 1993;694:36-47.
27. Wachters FM, Van Putten JWG, Kramer H, et al. Randomized multicenter phase III trial comparing gemcitabine in combination with cisplatin and epirubicin as first-line treatment in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol. 2002; abstract 1181.
28. Oosterbaan MJM, Dirks RJ, Vree TB, et al. Rapid quantitative determination of seven anthracyclines and their hydroxy metabolites in body fluids. J Chromatogr. 1984;306:323-332.
29. Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci. 1992;3:309-312.